GLP-1 Weight Management Programme

Medically supervised GLP-1 receptor agonist weight management programme using FDA-approved medications. Includes physician assessment, dose titration, dietary guidance, and ongoing metabolic monitoring.

The Artisan Health Clinic's GLP-1 Weight Management Programme offers a structured, doctor-supervised approach to medically assisted weight loss using glucagon-like peptide-1 (GLP-1) receptor agonists — a class of FDA-approved injectable medications that have demonstrated significant efficacy in clinical trials for both weight reduction and metabolic health improvement. GLP-1 receptor agonists work by mimicking the natural GLP-1 hormone, which regulates appetite, slows gastric emptying, and enhances insulin secretion in response to meals. The result is a meaningful reduction in hunger and caloric intake, sustained energy balance, and — particularly in patients with metabolic syndrome or prediabetes — improvement in blood glucose regulation and cardiovascular risk markers. The programme begins with a comprehensive initial consultation including body composition assessment, metabolic blood panel (fasting glucose, HbA1c, lipid profile, liver function, thyroid function), blood pressure, and a review of previous weight management attempts. The prescribing physician determines patient suitability based on BMI, comorbidities, and contraindications. Medication options include semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda), titrated from a starting dose over 4–20 weeks to maximise tolerability and efficacy. Monthly check-ins track weight, side effects, and metabolic markers. Dietary counselling integrated into the programme supports sustainable lifestyle change alongside medication. Patients typically achieve 10–15% body weight reduction over 6–12 months under medical supervision. The clinic provides injection training and ongoing education on managing common side effects such as nausea, which diminishes significantly after the initial titration phase. The programme is suitable for adults with a BMI ≥ 27 kg/m² with weight-related health concerns, or BMI ≥ 30 kg/m² without comorbidities.